About Penta
Who we are
Diversity and Inclusion
Our Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Calls for service
PentaTr@ining
Archivio
HCV treatment in children and young adults with HIV/HCV co-infection in Europe.
Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.
Once- versus twice-daily lopinavir/ritonavir in HIV-1 infected children: a randomised controlled trial (KONCERT/PENTA18/ANRS150).
ART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI
Long-term consequences of planned treatment interruption in HIV-1-infected children.
Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women
HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds
Atazanavir exposure is effective during pregnancy regardless of tenofovir use